Studies have shown κ-opioid receptor (KOR) abnormalities in addictive disorders, other central nervous system diseases, and Alzheimer's disease. We have developed the first set of agonist 11C-GR103545 and antagonist 11C-LY2795050 radiotracers for PET imaging of KOR in humans. Nonetheless, 11C-GR103545 displays protracted uptake kinetics and is not an optimal radiotracer. Here, we report the development and evaluation of 11C-methyl-(R)-4-(2-(3,4-dichlorophenyl)acetyl)-3-((diethylamino)methyl)piperazine-1-carboxylate (11C-EKAP) and its comparison with 11C-GR103545. Methods: EKAP was synthesized and assayed for in vitro binding affinities and then radiolabeled. PET studies were performed on rhesus monkeys. Blocking studies were performed with naloxone and the selective KOR antagonists LY2795050 and LY2456302. Arterial input functions were generated for use in kinetic modeling. Brain TACs were analyzed with multilinear analysis 1 to derive binding parameters. Results: EKAP has high KOR affinity (inhibition constant, 0.28 nM) and good selectivity in vitro. 11C-EKAP was prepared in good radiochemical purity. 11C-EKAP rapidly metabolized in plasma and displayed fast and reversible kinetics in brain, with peak uptake at less than 20 min after injection. Preblocking with naloxone (1 mg/kg) or LY2795050 (0.2 mg/kg) produced 84%-89% receptor occupancy, whereas LY2456302 (0.05 and 0.3 mg/kg) dose-dependently reduced 11C-EKAP-specific binding, thus demonstrating its binding specificity and selectivity in vivo. Mean multilinear analysis 1-derived nondisplaceable binding potential values were 1.74, 1.79, 1.46, 0.80, and 0.77 for cingulate cortex, globus pallidus, insula, striatum, and frontal cortex, respectively, consistent with the known KOR distribution in primate brains. Conclusion: We have successfully developed 11C-EKAP as a KOR agonist tracer with dual attractive imaging properties of fast uptake kinetics and high specific binding in vivo.
Studies have shown κ-opioid receptor (KOR) abnormalities in addictive disorders, other central nervous system diseases, and Alzheimer's disease. We have developed the first set of agonist 11C-GR103545 and antagonist 11C-LY2795050 radiotracers for PET imaging of KOR in humans. Nonetheless, 11C-GR103545 displays protracted uptake kinetics and is not an optimal radiotracer. Here, we report the development and evaluation of 11C-methyl-(R)-4-(2-(3,4-dichlorophenyl)acetyl)-3-((diethylamino)methyl)piperazine-1-carboxylate (11C-EKAP) and its comparison with 11C-GR103545. Methods: EKAP was synthesized and assayed for in vitro binding affinities and then radiolabeled. PET studies were performed on rhesus monkeys. Blocking studies were performed with naloxone and the selective KOR antagonists LY2795050 and LY2456302. Arterial input functions were generated for use in kinetic modeling. Brain TACs were analyzed with multilinear analysis 1 to derive binding parameters. Results: EKAP has high KOR affinity (inhibition constant, 0.28 nM) and good selectivity in vitro. 11C-EKAP was prepared in good radiochemical purity. 11C-EKAP rapidly metabolized in plasma and displayed fast and reversible kinetics in brain, with peak uptake at less than 20 min after injection. Preblocking with naloxone (1 mg/kg) or LY2795050 (0.2 mg/kg) produced 84%-89% receptor occupancy, whereas LY2456302 (0.05 and 0.3 mg/kg) dose-dependently reduced 11C-EKAP-specific binding, thus demonstrating its binding specificity and selectivity in vivo. Mean multilinear analysis 1-derived nondisplaceable binding potential values were 1.74, 1.79, 1.46, 0.80, and 0.77 for cingulate cortex, globus pallidus, insula, striatum, and frontal cortex, respectively, consistent with the known KOR distribution in primate brains. Conclusion: We have successfully developed 11C-EKAP as a KOR agonist tracer with dual attractive imaging properties of fast uptake kinetics and high specific binding in vivo.
Authors: Samuel S Newton; Johannes Thome; Tanya L Wallace; Yukihikko Shirayama; Lee Schlesinger; Norio Sakai; Jingshan Chen; Rachael Neve; Eric J Nestler; Ronald S Duman Journal: J Neurosci Date: 2002-12-15 Impact factor: 6.167
Authors: Matthew D Schmidt; Mark S Schmidt; Eduardo R Butelman; Wayne W Harding; Kevin Tidgewell; Daryl J Murry; Mary Jeanne Kreek; Thomas E Prisinzano Journal: Synapse Date: 2005-12-01 Impact factor: 2.562
Authors: Hayden T Ravert; Ursula Scheffel; William B Mathews; John L Musachio; Robert F Dannals Journal: Nucl Med Biol Date: 2002-01 Impact factor: 2.408
Authors: Peter S Talbot; Raj Narendran; Eduardo R Butelman; Yiyun Huang; Kim Ngo; Mark Slifstein; Diana Martinez; Marc Laruelle; Dah-Ren Hwang Journal: J Nucl Med Date: 2005-03 Impact factor: 10.057
Authors: Mika Naganawa; Songye Li; Nabeel Nabulsi; Shu-Fei Lin; David Labaree; Jim Ropchan; Hong Gao; Michael Mei; Shannan Henry; David Matuskey; Richard E Carson; Yiyun Huang Journal: J Nucl Med Date: 2020-03-13 Impact factor: 11.082
Authors: Giovanni Tangherlini; Frederik Börgel; Dirk Schepmann; Samuel Slocum; Tao Che; Stefan Wagner; Katrin Schwegmann; Sven Hermann; Nadine Mykicki; Karin Loser; Bernhard Wünsch Journal: ChemMedChem Date: 2020-09-01 Impact factor: 3.466
Authors: Jamie A Burns; Danielle S Kroll; Dana E Feldman; Christopher Kure Liu; Peter Manza; Corinde E Wiers; Nora D Volkow; Gene-Jack Wang Journal: Front Psychiatry Date: 2019-09-18 Impact factor: 4.157